- $445.91m
- $387.58m
- $180.46m
Brief: Kamada Announces Kedrion Exercised Option For 2-Year Extension Of Kedrab Distribution Agreement In U.S.
Brief: Kamada Announces $60 Million Private Placement With Fimi Opportunity Funds
Brief: Kamada Announces CFO Chaime Orlev To Remain In Role And Appointment Of Nir Livneh As Vice President, General Counsel And Corporate Secretary
Brief: Kamada Ltd Posts Q1 Loss Per Share $0.04
Brief: Kamada Announces Receipt Of Marketing Authorization For Glassia® For Treatment Of Alpha-1 Antitrypsin Deficiency In Switzerland
Factbox: US government to impose inflation penalties on 27 drugs
Brief: Kamada Ltd Posts Q4 Earnings Per Share $0.07
Brief: Kamada Reports Fiscal Year And Fourth Quarter 2022 Results
Brief: Kamada Continue To Project Annual Double-Digit Growth In Revenues And Profits In Foreseeable Years Ahead
Brief: Kamada Submits Application To The U.S. FDA To Manufacture Cytogam
Brief: Kamada Announces Planned Transition Of Chief Financial Officer
Brief: AcuCort Signs Its First Commercial Agreement For Zeqmelit
Brief: Kamada Reports Strong Third Quarter Financial Results And Reiterates 2022 Financial Guidance
Brief: Kamada Provides provides Update On Phase 3 Clinical Trial Of Inhaled AAT
Kamada jumps on $22 mln supply contract extension
Brief: Kamada Awarded $22 Million Extension Of Canadian Supply Tender
Soccer-Kamada and Mitoma strike as Japan breeze past United States
Brief: Kamada Ltd Reports Q2 Revenue Fell 3% To $23.6 Million
Brief: Kamada Announces Resolution To Labor Strike At Manufacturing Facility, 8-Year Deal Signed